Rayner Newsroom

First implantations of the Rayner M-flex^® Multifocal lens with added toric correction

Rayner is pleased to announce that on 28th June 2006, the first implantation of the Rayner M-flex^® Multifocal IOL with added toric correction was carried out.

The results of a study conducted at Prof. David J. Apple’s Salt Lake City laboratory and published this month*, suggest that in future intraocular lenses (IOLs) may be used to do more than simply restore vision: they could be used to deliver doses of antibiotic and anti-inflammatory drugs inside the eye.

In a recently published article (Ocular Surgery News, January 2006) entitled “Continuous edge design inhibits cell migration on hydrophilic IOL”, Mr. Ashok Vyas, Scarborough, UK commented that the Rayner C-flex^® IOL (570C) provided a “barrier to lens epithelial cell migration, even at the optic-haptic junction, because of a ridge that encircled the entire periphery of the lens”.

At the XXIII Congress of the European Society of Cataract and Refractive Surgeons (ESCRS) in Lisbon, Portugal, Rayner hosted two very well attended Satellite Meetings.

On Friday 9th September 2005, at the aptly named meeting, “We have the Edge – introducing the Rayner Multifocal”, delegates were not only introduced to Rayner’s new multifocal intraocular lens (M-flex®) but were also presented with the results from some new clinical studies for the C-flex® and Superflex^® intraocular lenses.

In a review of five years continuous experience of implanting Rayner’s Rayacryl^® lenses, surgeons Peter Bacon and Ashok Vyas from Scarborough Hospital, North Yorkshire, UK, jointly pronounce Rayner’s injectable lenses to be “very surgeon friendly” with an “excellent post-operative refraction accuracy”.

British IOL manufacturer, Rayner Intraocular Lenses Ltd., proudly announced today that it recently attained the coveted Therapeutic Goods Administration (TGA) clearance for sale of its intraocular lenses (IOLs) in Australia.

Rayner’s lenses are the first European IOLs to get TGA approval in over a decade. The TGA’s strict requirements over the years tended to restrict entry of new IOLs to Australia. This limited choice is about to change with Rayner’s entry into the market with the C-flex® injectable acrylic IOL system.

The first Rayner toric injectable lens was implanted by Dr Gerd Auffarth, assisted by Dr Luis Vargas. The intraocular lens was custom-made for a cataract patient with a pre-existing 6 dioptres of corneal astigmatism.

Rayner proudly introduces new, unique Quarter Dioptre Powers in the Centerflex® lens in the following ten quarter-powers:

On Friday 31st August, 2001, a Centerflex® users’ meeting was held prior to the ESCRS Congress in Amsterdam, The Netherlands. This proved to be a both very enjoyable and highly informative meeting with valuable contributions being made by several eminent guest speakers. Presentations were given by Professor M. Amon (Vienna, Austria), Dr. G. Auffarth (Heidelberg, Germany), Mr. A. Vyas (Scarborough, UK), Dr. L. Vargas (Charleston, USA) and Professor D. Apple (Charleston, USA).

Rayner Millennium Medal presented to David Apple in Chester.
On Friday 22 September 2000, Professor David J. Apple of the Storm Eye Institute, Medical University of South Carolina presented the Rayner Millennium Medal Lecture to delegates at the UKISCRS Annual Meeting in Chester, England.